A biopharmaceutical company with an original technology platform and mature industrialization capabilities. The company was founded in 2021, location in Zhejiang Province, who has developed a cutting-edge proprietary prokaryotic technology platform that utilizes prokaryotic organisms.
Virtu Pharmako focuses on the industrialization of biosimilars, innovative biologics, and biological products, primarily insulin and GLP-1 receptor agonists. Founder Dr. Hao Fan completed his postdoctoral research at the National Institutes of Health in the United States and possesses over 20 years of experience in biologics R&D and large-scale production, leading the development of more than 10 biosimilar large-scale production technologies. The company’s core team has an average of over 20 years of experience in the pharmaceutical field and has established a complete industrialization team encompassing R&D, production, quality control, and regulatory approvals.